Environmental signals polarize mononuclear phagocytes which can express different functional programmes. Fully polarized type I and type II (or alternatively activated) macrophages are the extremes of a continuum of functional states. Tumor-derived and T cell-derived cytokines stimulate tumor associated macrophages (TAM) to acquire a polarized type II phenotype. These functionally polarized cells, and similarly oriented or immature dendritic cells present in tumors, play a key role in subversion of adaptive immunity and in inflammatory circuits which promote tumor growth and progression.
SteinM., KeshavS., HarrisN., GordonS.: Interleukin 4 potently enhances murine mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med, 176: 287–292, 1992.
2.
GoerdtS., OrfanosC.E.: Other functions, other genes: alternative activation of antigen-presenting cells. Immunity, 10: 137–142, 1999.
3.
GordonS.: Alternative activation of macrophages. Nat Rev Immunol, 3: 23–35, 2003.
4.
MantovaniA., BottazziB., ColottaF., SozzaniS., RucoL.: The origin and function of tumor-associated macrophages. Immunol Today, 13: 265–270, 1992.
5.
BalkwillF., MantovaniA.: Inflammation and cancer: back to Virchow?Lancet, 357: 539–545, 2001.
6.
MillsC.D., KincaidK., AltJ.M., HeilmanM.J., HillA.M.: M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol, 164: 6166–6173, 2000.
7.
HamiltonT.A.: Molecular basis of macrophage activation: from gene expression to phenotypic diversity. In: The macrophage, 2nd edition, BourkeB., & LewisC. (Eds) Oxford University Press, Oxford, UK, 2002.
8.
MantovaniA., LocatiM., VecchiA., SozzaniS., AllavenaP.: Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol, 22: 328–336, 2001.
9.
DinarelloC.A.: Interleukin-1 and interleukin-1 antagonism. Blood, 77: 1627–1652, 1991.
10.
SozzaniS., GhezziS., IannoloG., LuiniW., BorsattiA., PolentaruttiN., SicaA., LocatiM., MackayC., WellsT.N., BiswasP., VicenziE., PoliG., MantovaniA.: Interleukin-10 increases CCR5 expression and HIV infection in human monocytes. J Exp Med, 187: 439–444, 1998.
11.
Penton-RolG., CotaM., PolentaruttiN., LuiniW., BernasconiS., BorsattiA., SicaA., LaRosaG.J., SozzaniS., PoliG., MantovaniA.: Upregulation of CCR2 chemokine receptor expression and increased susceptibility to the multitropic HIV strain 89.6 in monocytes exposed to glucocorticoid hormones. J Immunol, 163: 3524–3529, 1999.
12.
BonecchiR., FacchettiF., DusiS., LuiniW., LissandriniD., SimmelinkM., LocatiM., BernasconiS., AllavenaP., BrandtE., RossiF., MantovaniA., SozzaniS.: Induction of functional IL-8 receptors by IL-4 and IL-13 in human monocytes. J Immunol, 164: 3862–3869, 2000.
13.
SicaA., SaccaniA., BorsattiA., PowerC.A., WellsT.N., LuiniW., PolentaruttiN., SozzaniS., MantovaniA.: Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytes. J Exp Med, 185: 969–974, 1997.
14.
Penton-RolG., PolentaruttiN., LuiniW., BorsattiA., MancinelliR., SicaA., SozzaniS., MantovaniA.: Selective inhibition of expression of the chemokine receptor CCR2 in human monocytes by IFN-γ. J Immunol, 160: 3869–3873, 1998.
15.
D'AmicoG., FrascaroliG., BianchiG., TransidicoP., DoniA., VecchiA., SozzaniS., AllavenaP., MantovaniA.: Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. Nature Immunol:1, 387–391, 2000.
16.
MantovaniA., SozzaniS.: Chemokines. In: The cytokine network, BalkwillF. (ed), pp 103–125, Oxford University Press, Oxford, 2000.
17.
WatanabeK., JoseP.J., RankinS.M.: Eotaxin-2 generation is differentially regulated by lipopolysaccharide and IL-4 in monocytes and macrophages. J Immunol, 168: 1911–1918, 2002.
18.
BonecchiR., SozzaniS., StineJ.T., LuiniW., D'AmicoG., AllavenaP., ChantryD., MantovaniA.: Divergent effects of IL-4 and interferon gamma on macrophage-derived chemokine (MDC) production: an amplification circuit of polarized T helper 2 responses. Blood, 92: 2668–2671, 1998.
19.
KodeljaV., MullerC., PolitzO., HakijN., OrfanosC.E., GoerdtS.: Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol, 160: 1411–1418, 1998.
20.
VulcanoM., StruyfS., ScapiniP., CassatellaM., BernasconiS., BonecchiR., CalledA., PennaG., AdoriniL., LuiniW., MantovaniA., Van DammeJ., SozzaniS.: Unique regulation of CCL18 production by maturing dendritic cells. J Immunol, 170: 3843–3849, 2003.
21.
RollinsB.: Chemokines and cancer, Humana Press, Totowa, NJ, 1999.
22.
MantovaniA.: The chemokine system: redundancy for robust outputs. Immunol Today, 20: 254–257, 1999.
23.
YangJ., RichmondA.: Constitutive IkappaB kinase activity correlates with nuclear factor- kappaB activation in human melanoma cells. Cancer Res, 61: 4901–4909, 2001.
24.
DhawanP., RichmondA.: A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem, 277: 7920–7928, 2002.
25.
BottazziB., PolentaruttiN., AceroR., BalsariA., BoraschiD., GhezziP., SalmonaM., MantovaniA.: Regulation of the macrophage content of neoplasms by chemoattractants. Science, 220: 210–212, 1983.
26.
NesbitM., SchaiderH., MillerT.H., HerlynM.: Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol, 166: 6483–6490, 2001.
27.
MrowietzU., SchwenkU., MauneS., BartelsJ., KupperM., FichtnerI., SchroderJ.M., SchadendorfD.: The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer, 79: 1025–1031, 1999.
28.
LuboshitsG., ShinaS., KaplanO., EngelbergS., NassD., Lifshitz-MercerB., ChaitchikS., KeydarI., Ben-BaruchA.: Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res, 59: 4681–4687, 1999.
29.
AzenshteinE., LuboshitsG., ShinaS., NeumarkE., ShahbazianD., WeilM., WiglerN., KeydarI., Ben-BaruchA.: The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res, 62: 1093–1102, 2002.
30.
HaghnegahdarH., DuJ., WangD., StrieterR.M., BurdickM.D., NanneyL.B., CardwellN., LuanJ., Shattuck-BrandtR., RichmondA.: The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J Leukoc Biol, 67: 53–62, 2000.
31.
LinE.Y., NguyenA.V., RussellR.G., PollardJ.W.: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med, 193: 727–740, 2001.
32.
BarleonB., SozzaniS., ZhouD., WeichH.A., MantovaniA., MarmeD.: Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the flt-1/VEGF receptor. Blood, 87: 3336–3343, 1996.
33.
DuyndamM.C., HilhorstM.C., SchluperH.M., VerheulH.M., van DiestP.J., KraalG., PinedoH.M., BovenE.: Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol, 160: 537–548, 2002.
34.
NowickiA., SzenajchJ., OstrowskaG., WojtowiczA., WojtowiczK., KruszewskiA.A., MaruszynskiM., AukermanS.L., Wiktor-JedrzejczakW.: Impaired tumor growth in colony-stimulating factor 1 (CSF-l)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int J Cancer, 65: 112–119, 1996.
35.
LocatiM., DeuschleU., MassardiM.L., MartinezF.O., SironiM., SozzaniS., BartfaiT., MantovaniA.: Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J Immunol, 168: 3557–3562, 2002.
36.
KeaneM.P., StrieterR.M.: The role of CXC chemokines in the regulation of angiogenesis. In: Chemokines: chemical immunology, MantovaniA. (ed), vol 72, pp 86–101, Karger, Basel, 1999.
37.
WangJ.M., ChertovO., ProostP., LiJ.J., MentonP., XuL., SozzaniS., MantovaniA., GongW., SchirrmacherV., Van DammeJ., OppenheimJ.J.: Purification and identification of chemokines potentially involved in kidney-specific metastasis by a murine lymphoma variant: induction of migration and NFkB activation. Int J Cancer, 75: 900–907, 1998.
38.
MullerA., HomeyB., SotoH., GeN., CatronD., BuchananM.E., McClanahanT., MurphyE., YuanW., WagnerS.N., BarreraJ.L., MoharA., VerasteguiE., ZlotnikA.: Involvement of chemokine receptors in breast cancer metastasis. Nature, 410: 50–56, 2001.
39.
ScottonC.J., WilsonJ.L., ScottK., StampG., WilbanksG.D., FrickerS., BridgerG., BalkwillF.R.: Epithelial cancer cell migration: a role for chemokine receptors?Cancer Res, 61: 4961–4965, 2001.
40.
OpdenakkerG., Van DammeJ.: Chemotactic factors, passive invasion and metastasis of cancer cells. Immunol Today, 13: 463–464, 1992.
41.
CurinoA., MitolaD.J., AaronsonH., McMahonG.A., RajaK., KeeganA.D., LawrenceD.A., BuggeT.H.: Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages. Oncogene, 21: 8830–8842, 2002.
42.
AdiniA., KornagaT., FiroozbakhtF., BenjaminL.E.: Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res, 62: 2749–2752, 2002.
43.
SicaA., SaccaniA., BottazziB., BernasconiS., AllavenaP., GaetanoB., FeiF., LaRosaG., ScottonC., BalkwillF., MantovaniA.: Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J Immunol, 164: 733–738, 2000.
44.
NaylorM.S., StampG.W., FoulkesW.D., EcclesD., BalkwillF.R.: Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest, 91: 2194–2206, 1993.
45.
SicaA., SaccaniA., BottazziB., PolentaruttiN., VecchiA., van DammeJ., MantovaniA.: Autocrine production of IL-10 mediates defective IL-12 production and NF-kB activation in tumor-associated macrophages. J Immunol, 164: 762–767, 2000.
46.
KambayashiT., AlexanderH.R., FongM., StrassmannG.: Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol, 154: 3383–3390, 1995.
47.
LoercherA.E., NashM.A., KavanaghJ.J., PlatsoucasC.D., FreedmanR.S.: Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol, 163: 6251–6260.
48.
MaedaH., KuwaharaH., IchimuraY., OhtsukiM., KurakataS., ShiraishiA.: TGF-beta enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J Immunol, 155: 4926–4932, 1995.
49.
KimJ., ModlinR.L., MoyR.L., DubinettS.M., McHughT., NickoloffB.J., UyemuraK.: IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol, 155: 2240–2247, 1995.
50.
AllavenaP., SicaA., VecchiA., LocatiM., SozzaniS., MantovaniA.: The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol Rev, 177: 141–149, 2000.
51.
ScarpinoS., StoppacciaroA., BalleriniF., MarchesiM., PratM., StellaM.C., SozzaniS., AllavenaP., MantovaniA., RucoL.P.: Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cell to release chemokines active in recruiting dendritic cells. Am J Pathol, 156: 831–837, 2000.
52.
HerbeuvalJ.P., LambertC., SabidoO., CottierM., FournelP., DyM., GeninC.: Macrophages from cancer patients: analysis of TRAIL, TRAIL receptors, and colon tumor cell apoptosis. J Natl Cancer Inst, 95: 611–621, 2003.
53.
DinapoliM.R., CalderonC.L., LopezD.M.: The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduced expression of the inducible nitric oxide synthase gene. J Exp Med, 183: 1323–1329, 1996.
54.
KlimpA.H., HollemaH., KempingaC., Van der ZeeA.G., de VriesE.G., DaemenT.: Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res, 61: 7305–7309, 2001.
55.
MantovaniA., SicaA.: The jury of radicals is still out. Trends immunology, 24: 234, 2003.
56.
Van Den BruleF., CalificeS., GamierF., FernandezP.L., BerchuckA., CastronovoV.: Galectin-1 accumulation in ovarian carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. Lab Invest, 83: 377–386, 2003.
57.
CorreaS.G., SotomayorCE, AokiMP, MaldonatoCA, RabinovichGA: Opposite effects of galectin-1 on alternative metabolic pathways of L-arginine in resident, inflammatory, and activated macrophages. Glycobiology, 13: 119–128, 2003.
58.
GrimshawM.J., BalkwillF.R.: Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation: a potential mechanism. Eur J Immunol, 31: 480–489, 2001.
LeekR.D., LewisC.E., WhitehouseR., GreenallM., ClarkeJ., HarrisA.L.: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res, 56: 4625–4629, 1996.
61.
LeekR.D., LandersR.J., HarrisA.L., LewisC.E.: Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer, 79: 991–995, 1999.
62.
LewisJ.S., LandersR.J., UnderwoodJ.C., HarrisA.L., LewisC.E.: Expression of vascular endothelial growth factor by macrophages is up- regulated in poorly vascularized areas of breast carcinomas. J Pathol, 192: 150–158, 2000.
63.
TalksK.L., TurleyH., GatterK.C., MaxwellP.H., PughC.W., RatcliffeP.J., HarrisA.L.: The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol, 157: 411–421, 2000.
64.
CrowtherM., BrownN.J., BishopE.T., LewisC.E.: Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol, 70: 478–490, 2001.
GuL., TsengS., HornerR.M., TarnC., LodaM., RollinsB.J.: Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature, 404, 407–411, 2000.
67.
Van den BergA., VisserL., PoppemaS.: High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol, 154: 1685–1691, 1999.
IellemA., MarianiM., LangR., RecaldeH., Panina-BordignonP., SinigagliaF., D'AmbrosioD.: Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med, 194: 847–853, 2001.
70.
SchutyserE., StruyfS., ProostP., OpdenakkerG., LaureysG., VerhasseltB., PeperstraeteL., Van de PutteI., SaccaniA., AllavenaP., MantovaniA., Van DammeJ.: Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem, 277: 24584–24593, 2002.
DongZ., YonedaJ., KumarR., FidlerI.J.: Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor. J Exp Med, 188: 755–763, 1998.
73.
YoungM.R., PetruzzelliG.J., KolesiakK., AchilleN., LathersD.M., GabrilovichD.I.: Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34(+) progenitor cells. Hum Immunol, 62: 332–341, 2001.
BellD., ChomaratP., BroylesD., NettoG., HarbG.M., LebecqueS., ValladeauJ., DavoustJ., PaluckaK.A., BanchereauJ.: In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med, 190: 1417–1426, 1999.
76.
ZouW., MachelonV., Coulomb-L'HerminA., BorvakJ., NomeF., IsaevaT., WeiS., KrzysiekR., Durand-GasselinI., GordonA., PustilnikT., CurielD.T., GalanaudP., CapronF., EmilieD., CurielT.J.: Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Med, 7: 1339–1346, 2001.
77.
NegusR.P., StampG.W., HadleyJ., BalkwillF.R.: Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol, 150: 1723–1734, 1997.
78.
KleeffJ., KusamaT., RossiD.L., IshiwataT., MaruyamaH., FriessH., BuchlerM.W., ZlotnikA., KorcM.: Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer, 81: 650–657, 1999.
79.
FushimiT., KojimaA., MooreM.A., CrystalR.G.: Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest, 105: 1383–1393, 2000.
80.
PennaG., SozzaniS., AdoriniL.: Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J Immunol, 167: 1862–1866, 2001.
81.
ChauxP., MoutetM., FaivreJ., MartinF., MartinM.: Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest, 74: 975–983, 1996.
82.
NestleF.O., BurgG., FahJ., Wrone-SmithT., NickoloffB.J.: Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol, 150: 641–651, 1997.
EnkA.H., JonuleitH., SalogaJ., KnopJ.: Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer, 73: 309–316, 1997.
85.
FiorettiF., FradeliziD., StoppacciaroA., RamponiS., RucoL., MintyA., SozzaniS., GarlandaC., VecchiA., MantovaniA.: Reduced tumorigenicity and augmented leukocyte infiltration after MCP-3 gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J Immunol, 161: 342–346, 1998.
86.
DhodapkarM.V., SteinmanR.M., KrasovskyJ., MunzC., BhardwajN.: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med, 193: 233–238, 2001.
87.
RoncaroloM.G., LevingsM.K., TraversariC.: Differentiation of T regulatory cells by immature dendritic cells. J Exp Med, 193: F5–F9, 2001.
88.
ShimizuJ., YamazakiS., SakaguchiS.: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol, 163: 5211–5218, 1999.
89.
SchofieldJ.B., AlsanjariN.A., DavisJ., MacLennanK.A.: Eosinophilic granuloma of lymph nodes associated with metastatic papillary carcinoma of the thyroid. Histopathology, 20: 181–183, 1992.
90.
ThompsonL.D., WenigB.M., AdairC.F., SmithB.C., HeffessC.S.: Langerhans cell histiocytosis of the thyroid: a series of seven cases and a review of the literature. Modern Pathology, 9: 145–149, 1996.
91.
SafaliM., McCutcheonJ.M., WrightD.H.: Langerhans cell histiocytosis of lymph nodes: draining a papillary carcinoma of the thyroid. Histopathology, 30: 599–603, 1997.
92.
LindleyR., HoileR., SchofieldJ., Ashton-KeyM.: Langerhans cell histiocytosis associated with papillary carcinoma of the thyroid. Histopathology, 32: 180, 1998.
93.
Menetrier-CauxC., MontmainG., DieuM.C., BainC., FavrotM.C., CauxC., BlayJ.Y.: Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood, 92: 4778–4791, 1998.
94.
KalinskiP., SchuitemakerJ.H., HilkensC.M., KapsenbergM.L.: Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+ CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol, 161: 2804–2809, 1998.
95.
HuangM., SharmaS., MaoJ.T., DubinettS.M.: Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol, 157: 5512–5520, 1996.
96.
la SalaA., SebastianiS., FerrariD., Di VirgilioF., IdzkoM., NorgauerJ., GirolomoniG.: Dendritic cells exposed to extracellular adenosine triphosphate acquire the migratory properties of mature cells and show a reduced capacity to attract type 1 T lymphocytes. Blood, 99: 1715–1722, 2002.
97.
KatakiA., ScheidP., PietM., MarieB., MartinetN., MartinetY., VignaudJ.M.: Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med, 140: 320–328, 2002.
98.
CoussensL.M., TinkleC.L., HanahanD., WerbZ.: MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103: 481–490, 2000.
HiratsukaS., NakamuraK., IwaiS., MurakamiM., ItohT., KijimaH., ShipleyJ.M., SeniorR.M., ShibuyaM.: MMP-9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell, 2: 289–300, 2002.
101.
SchoppmannS.F., BirnerP., StocklJ., KaltR., UllrichR., CaucigC., KriehuberE., NagyK., AlitaloK., KerjaschkiD.: Tumor-Associated macrophages express lymphatic endothelial growth factors and are realated to peritumoral lymphoangiogenesis. Am J Pathol, 161: 947–956, 2002.
102.
HotchkissK.A., AshtonA.W., KleinR.S., LenziM.L., ZhuG.H., SchwartzE.L.: Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorilase mediate human endothelial cell migration. Cancer Res, 63: 527–533, 2003.
103.
MooreB.B., PaineR3rd, ChristensenP.J., MooreT.A., SitterdingS., NganR., WilkeC.A., KuzielW.A., ToewsG.B.: Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol, 167: 4368–4377, 2001.
